Kneat Com - KSIOF STOCK NEWS

Kneat (TSX: KSI) (OTC: KSIOF), a company specializing in digitizing and automating validation and quality processes, has announced it will release its Q4 and full-year 2024 financial results on February 26, 2025, after TSX market close.

The company will host a conference call and Q&A session for sell-side analysts via webcast on February 27, 2025, at 09:00 ET (14:00 GMT). CEO Eddie Ryan and CFO Hugh Kavanagh will lead the presentation. The financial results will be accessible through the Financial Information section of Kneat's Investors page on their website.

Kneat (TSX: KSI, OTCQX: KSIOF) has secured a three-year Master Services Agreement with a major multinational consumer food and drink producer to digitize its validation processes. The European-headquartered company will initially implement Kneat's solutions for Equipment and Computer System Validation within its health sciences division, which employs over 5,000 people.

The agreement allows for potential expansion of Kneat's services across all affiliate companies and business divisions. This partnership demonstrates Kneat's expanding reach beyond traditional life sciences into consumer products, particularly for companies requiring validation regulatory compliance. The digitization initiative aims to help companies mitigate risk and protect their established brands.

Kneat.com (TSX: KSI, OTCQX: KSIOF) has secured a three-year Master Services Agreement with a major global therapeutics company to digitize its validation processes. The unnamed European company employs over 20,000 people across 100+ countries and operates more than ten manufacturing sites globally.

The client company provides supplies for Life Sciences organizations, focusing on research, clinical trials, manufacturing, diagnosis, and treatment. They will initially implement Kneat Gx for commissioning, qualification, and validation of manufacturing equipment and facilities. The partnership represents continued momentum for Kneat in attracting global Life Sciences leaders to its platform.

Kneat (TSX: KSI, OTCQC: KSIOF) has secured a three-year Master Services Agreement with a global medical device manufacturer to digitize their computer system validation (CSV) processes. The client, which operates in over 100 countries with manufacturing facilities in the United States, Latin America, and Europe, is part of a larger life sciences organization employing more than 15,000 people worldwide.

The agreement aims to transform the client's manual hybrid paper process into a streamlined digital solution, enhancing collaboration, visibility, speed, and harmonization for validating multiple IT systems. Kneat Gx was selected for its demonstrated ability to reduce validation costs while maintaining high compliance standards, with potential for expansion to additional validation use cases within the organization.

Kneat has signed a three-year Master Services Agreement with ALTEN SA, a global Engineering and IT Services company. ALTEN will use Kneat Gx to digitize validation processes for itself and its Life Sciences customers. With nearly 60,000 employees across 30+ countries, ALTEN serves pharmaceutical, biotechnology, medical device, and related industries. The implementation will begin with Commissioning and Qualification processes, aiming to improve efficiency and data integrity in validation workflows.

Kneat reported strong Q3 2024 financial results with total revenue reaching $12.8 million, up 52% year-over-year. The company achieved significant growth in key metrics, including a 78% increase in gross profit to $9.8 million and improved gross margin of 77%. SaaS revenue grew 48% to $11.5 million, while Annual Recurring Revenue (ARR) increased 59% to $49.9 million. The company reported positive net income of $1.2 million compared to a loss of $3.6 million in Q3 2023. Additionally, Kneat completed a bought deal offering raising $35.6 million and secured new strategic customers in the pharmaceutical and medical devices sectors.

A global medical devices manufacturer has signed a three-year Master Services Agreement with Kneat to digitize its validation processes. The client, headquartered in Germany, employs over 11,000 people and operates 30+ production sites across 15 countries in Europe, Asia and the Americas. The company provides solutions to pharma, biotech and cosmetic industries, including pharmaceutical packaging, drug delivery systems, diagnostic devices, and digital healthcare solutions. They plan to implement the Kneat Gx platform for Commissioning, Qualification and Validation (CQV) processes.